Sugi Predict

Sugi Predict / Compounds / SCHEMBL19451341

SCHEMBL19451341

SCHEMBL19451341

NCCOCCOCCNc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 4/20 0.65
▸ CRBN Q96SW2 9/20 0.58
▸ MAP1LC3B Q9GZQ8 5/20 0.58
▸ IKZF3 Q9UKT9 3/20 0.58
▸ DDB1 Q16531 2/20 0.58
▸ IKZF1 Q13422 2/20 0.58
▸ TNF P01375 2/20 0.58
▸ BRD4 O60885 1/20 0.58
▸ IL1B P01584 1/20 0.58
▸ HDAC3 O15379 1/20 0.51
▸ HDAC1 Q13547 1/20 0.51
▸ CSNK1A1 P48729 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30438189 1.00 STAT3 (0.65) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL20913625 1.00 STAT3 (0.65) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL30376389 1.00 STAT3 (0.65) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL19451338 1.00 STAT3 (0.65) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL19451343 1.00 STAT3 (0.65) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL30241717 1.00 STAT3 (0.65) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL19451342 0.99 STAT3 (0.63) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL30437927 0.99 STAT3 (0.63) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL26815429 0.97 STAT3 (0.61) STAT3CRBNMAP1LC3BIKZF3DDB1
SCHEMBL19451359 0.95 STAT3 (0.64) STAT3CRBNMAP1LC3BIKZF3DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110615779-B Process for preparing lenalidomide derivatives 上海科技大学 2023-03-24 — — CN claimed
CN-110615779-A Process for preparing lenalidomide derivatives 上海科技大学 2019-12-27 — — CN claimed
US-20240101534-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-03-28 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230150974-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
US-20230150974-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 — — US disclosed
CN-115666575-A Compound and use thereof 福宏治疗公司 2023-01-31 — — CN disclosed
US-20220411432-A1 MDM2 PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2022-12-29 — — US disclosed
WO-2022109396-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-27 — — WO disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
WO-2020069125-A1 DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-02 — — WO disclosed
WO-2020069125-A1 DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-04-02 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190169195-A1 BET PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2019-06-06 — — US disclosed
US-20190127387-A1 MDM2 PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2019-05-02 — — US disclosed
US-20190119289-A1 MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION UNIV MICHIGAN REGENTS (US) 2019-04-25 — — US disclosed
US-20190119289-A1 MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION UNIV MICHIGAN REGENTS (US) 2019-04-25 — — US disclosed
WO-2017180417-A1 BET PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-19 — — WO disclosed
WO-2017176957-A1 MDM2 PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101534-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 STAT3 3997/4885CRBN 163/4885MAP1LC3B 677/4885
US-20190119289-A1 MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION MDM2, CD74, TNFSF10 STAT3 719/4885CRBN 151/4885MAP1LC3B 1358/4885
US-20230150974-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB STAT3 3892/4885CRBN 179/4885MAP1LC3B 346/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 STAT3 145/4885CRBN 187/4885MAP1LC3B 1569/4885
US-20220411432-A1 MDM2 PROTEIN DEGRADERS MDM2, TP53, TP53BP1 STAT3 1275/4885CRBN 605/4885MAP1LC3B 1372/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 STAT3 145/4885CRBN 187/4885MAP1LC3B 1569/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 STAT3 145/4885CRBN 187/4885MAP1LC3B 1569/4885
US-20190169195-A1 BET PROTEIN DEGRADERS BRD4, BET1, BRD1 STAT3 484/4885CRBN 195/4885MAP1LC3B 1362/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 STAT3 145/4885CRBN 187/4885MAP1LC3B 1569/4885
US-20190127387-A1 MDM2 PROTEIN DEGRADERS MDM2, TP53, TP53BP1 STAT3 1275/4885CRBN 605/4885MAP1LC3B 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback